The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Berchuck, Jacob E.; Facchinetti, Francesco; DiToro, Daniel; Baiev, Islam; Majeed, Umair; Reyes, Stephanie; Chen, Christopher; Zhang, Karen; Sharman, Reya; Usón, Pedro Luiz Serrano; Maurer, Jordan; Shroff, Rachna T.; Pritchard, Colin C.; Wu, Meng-Ju; Catenacci, Daniel V.T.; Javle, Milind; Friboulet, Luc; Hollebecque, Antoine; Bardeesy, Nabeel; Lennerz, Jochen K.; Tan, Benjamin; Borad, Mitesh J.; Parikh, Aparna R.; Kiedrowski, Lesli A.; Kelley, Robin Kate; Mody, Kabir; Juric, Dejan; Goyal, Lipika

doi:10.1016/j.annonc.2022.09.150

Cited by 68 publications

(47 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several retrospective studies evaluating plasma ctDNA have established its utility as a source of biomarkers in the treatment of BTC. In a study of plasma cfDNA from over 1600 patients, Berchuck et al 1 . found genetic alterations in 84% of patients with 44% of them being actionable.…”

Section: Cancer Type Fluid Methods Mutation Detection (%)A Matched Tumormentioning

confidence: 99%

Promise of bile circulating tumor DNA in biliary tract cancers

Kearney

Weighill

Yeh

2023

Cancer

View full text Add to dashboard Cite

An explosion of technological advances has facilitated the unprecedented use of liquid biopsy methods to isolate and interrogate circulating tumor DNA for precision oncology approaches. Liquid biopsy samples are not isolated to plasma but include bodily fluids such as urine and bile. In this issue, Ohyama et al. present a prospective study of patients with biliary tract cancers who underwent cell‐free DNA (cfDNA) isolation from bile and plasma, further demonstrating the feasibility and promise of bile cfDNA for biliary tract malignancies.

show abstract

Section: Cancer Type Fluid Methods Mutation Detection (%)A Matched Tumormentioning

confidence: 99%

Promise of bile circulating tumor DNA in biliary tract cancers

Kearney

Weighill

Yeh

2023

Cancer

View full text Add to dashboard Cite

show abstract

“…Finally, for future trials evaluating FGFR inhibitors, data from co-occurring mutations would be necessary to be informed and included in the report of outcomes. Furthermore, ctDNA would need to be incorporated as the choice for detecting acquired mutations and co-occurring mutations related to primary and secondary resistance to FGFR inhibitors [45,46].…”

Section: Challenges and Perspectivesmentioning

confidence: 99%

“…Furthermore, ctDNA would need to be incorporated as the choice for detecting acquired mutations and cooccurring mutations related to primary and secondary resistance to FGFR inhibitors. 45,46…”

Section: Challenges and Perspectivesmentioning

confidence: 99%

Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond

Usón

Borad

2023

Semin Liver Dis

View full text Add to dashboard Cite

FGFR2 Inhibitors are now being included in the treatment guidelines of multiple countries for patients with advanced cholangiocarcinoma (CCA). Activation of the FGF-FGFR pathway is related to proliferation and tumor progression. Targeting the FGF-FGFR pathway is effective and can yield durable responses in patients with CCA harboring FGFR2 fusions or rearrangements. In this review article, we address molecules and clinical trials evaluating FGFR inhibitors in advanced CCA. We will further discuss identified mechanisms of resistance and the strategies to overcome it. The incorporation of next-generating sequencing in advanced CCA and circulating tumor DNA on disease progression will unveil mechanisms of resistance and improve the development of future clinical trials and more selective drugs and combinations.

show abstract

“…Moreover, an increased understanding of pCCA genetics could identify subtypes with prognostic importance. In fact, genetic alterations in the FGFR and DNA damage repair alteration pathways were associated with less aggressive disease, a superior response to first-line chemotherapy, and improved OS in LT for iCCA [43] .…”

Section: Neoadjuvant Chemoradiation Molecular Profilingmentioning

confidence: 99%

Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward?

Dopazo¹,

Charco²

2023

Hepatoma Res

View full text Add to dashboard Cite

Perihilar cholangiocarcinoma (pCCA) is a challenging disease with limited options. Surgical resection and adjuvant therapy remain the only established treatment for those with resectable disease. Since the publication of the Mayo protocol in 2000, neoadjuvant chemoradiation and liver transplantation have become the standard of care in selected patients with unresectable de novo pCCA or resectable pCCA arising under primary sclerosing cholangitis. However, its application is diverse worldwide, and the need for donor organs is one of the main limitations. Also, differences in the neoadjuvant regimen used were observed. In this review, we discuss the latest results of this approach, the recommended tools for diagnostic work-up, and advances in systemic therapy to improve patient selection and long-term survival.

show abstract

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Cited by 68 publications

References 90 publications

Promise of bile circulating tumor DNA in biliary tract cancers

Promise of bile circulating tumor DNA in biliary tract cancers

Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond

Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward?

Contact Info

Product

Resources

About